A Medicare Prescription Drug Benefit: Exploring Issues Raised in a CBO Report
November 25, 2002
Robin J. Strongin, Consultant
This meeting used an October 2002 U. S. Congressional Budget Office (CBO) report, Issues in Designing a Prescription Drug Benefit for Medicare, as a springboard for discussion of the policy implications, complexities, and underlying challenges inherent in the design of a Medicare prescription drug benefit. The speakers, including CBO analysts who contributed to the report as well as a panel of Capitol Hill staff and other experts, explored the factors likely to affect passage and the effects that variously structured prescription drug benefits would have on other health services and programs.
Steven M. Lieberman, Executive Associate Director, Congressional Budget Office; Jonathan Blum, Professional Staff Member (D), Committee on Finance, U.S. Senate; Joel C. White, Professional Staff Member (R), Subcommittee on Health, Committee on Ways and Means, U.S. House of Representatives; Kathleen A. Buto, Vice President, Health Policy, Johnson & Johnson; James Baumgardner, Ph.D., Deputy Assistant Director, Health Policy, Congressional Budget Office; Linda Fishman, Health Policy Director (R), Committee on Finance, U.S. Senate; Bridgett Taylor, Professional Staff Member (D), Committee on Energy and Commerce, U.S. House of Representatives